ArticleCase reports in pathology2025
Simultaneous Lymphoepithelioma-Like and Plasmacytoid Subtypes of Urothelial Carcinoma, Along With Prostatic Adenocarcinoma With Clinical Follow-Up.
Article in Case reports in pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoepithelioma-like urothelial carcinoma (LELUC) and plasmacytoid urothelial carcinoma (PUC) are rare subtypes. We report a case of simultaneous urothelial carcinoma composed of LELUC and PUC subtypes, along with prostatic adenocarcinoma, with successful clinical management by immunotherapy. The patient, a 54-year-old man with a 40 pack-year smoking history, presented with gross hematuria and dysuria. Imaging revealed focal bladder wall thickening. The patient underwent transurethral resection of bladder tumor (TURBT), followed by cystoprostatectomy. The TURBT revealed LELUC, with muscle invasion. The subsequent cystoprostatectomy specimen displayed a 6.0 cm ulcerative mass, which had focal penetration through the urinary bladder wall. Microscopically, the tumor consisted of sheets of enlarged and pleomorphic tumor cells, mixed with a lymphoplasmacytic infiltrate. Focal plasmacytoid and occasional signet ring cell-like morphologies were observed. Rare tumor cells showed positivity for GATA-3 and p63 immunostains, while the plasmacytoid tumor cells exhibited loss of E-cadherin expression. Additionally, adenocarcinoma of the prostate was present, with a Gleason score of 3 + 3, involving 2% of the prostate tissue. The diagnoses of LELUC, comprising 95% of the tumor, PUC, comprising 5%, and prostatic adenocarcinoma were made. Molecular studies revealed a high tumor mutational burden, and the tumor exhibited PD-L1 expression. The patient received adjuvant immunotherapy with Pembrolizumab and showed no evidence of disease for 3 years up to the time of this report. Morphologic recognition of the various subtypes of urothelial carcinoma, supported by immunohistochemistry, is essential for the proper clinical management of patients. A search of the literature on PubMed revealed no similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.